<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651166</url>
  </required_header>
  <id_info>
    <org_study_id>RA-2020-050</org_study_id>
    <nct_id>NCT04651166</nct_id>
  </id_info>
  <brief_title>Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation</brief_title>
  <official_title>Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic tranexamic acid has shown been shown to reduce maternal mortality from&#xD;
      postpartum hemorrhage with no adverse effects, but has not been studied to reduce bleeding&#xD;
      complications with dilation and evacuation (D&amp;E). We propose a randomized, double-blinded,&#xD;
      placebo-controlled pilot study to determine whether routine use of intravenous (IV)&#xD;
      tranexamic acid will decrease the need for interventions to control bleeding at the time of&#xD;
      D&amp;E at 16 to 24 weeks gestation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intervention to control blood loss</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Rate at which providers perform interventions to control blood loss during D&amp;E procedures</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Abortion</condition>
  <condition>Dilation and Evacuation</condition>
  <condition>Hemorrhage</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>1g tranexamic acid mixed in 100mL saline or lactated ringer</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mL saline or lactated ringers</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Requesting pregnancy termination&#xD;
&#xD;
          -  Intrauterine pregnancy at 16 to 24 weeks gestation&#xD;
&#xD;
          -  Participants must be willing and capable of giving informed consent and able to&#xD;
             understand and sign written consents in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of thromboembolic events (i.e. deep vein thrombosis, stroke, pulmonary&#xD;
             embolism)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marit Pearlman Shapiro</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marit Pearlman Shapiro</last_name>
    <phone>8082036508</phone>
    <email>maritps@hawaii.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Marit Pearlman Shapiro</investigator_full_name>
    <investigator_title>Complex Family Planning Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

